Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week
Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for the week of December 16th – December 22nd, 2019.
Without further ado, let’s get started.
Battley’s Departure From Aurora Could Be a Warning Sign for Investors
Shares of TCAN Stock Soared Nearly 20% Today in Reaction to the Favourable News
TransCanna Holdings (CSE:TCAN) (OTC:TCNAF) (FSE: TH8) announced its wholly-owned subsidiary Lyfted Farms received a unanimous recommendation in support of approving its Daly Project. The Daly Project is a 196,000 Sq Ft Cultivation, Manufacturing & Distribution Facility in Modesto, California.
Valens Saw Significant Growth in its White Label and Cannabis 2.0 Product Sales
Hollister Believes They Have What it Takes to Be a Dominant Player in the Golden State
36,800,000 Units Were Sold Under the New TGOD Offering
The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF) has finally closed its bought deal financing announced in late November. The firm closed the bought deal on an oversubscribed basis, raising a gross figure of $27.6 million.
Tilray Did Not Make Any Cash Payment in Connection With the Merger
Tilray Inc (NASDAQ:TLRY) announced that it has closed its merger with private equity firm Privateer Holdings. Each Privateer stockholder who acquired shares of Tilray in the merger is subject to a lockup agreement.
These Trulieve Super-Voting Shares Would Have Come Free in Late January 2020
Shares of CURA Stock Jumped 7% in Reaction to the Funding Announcement
Analyst Announces New Sell Rating on ACB Stock and Shockingly Bearish $0 Price Target
In a note to clients, GLJ Research analyst Gordon Johnson placed a ‘Sell’ rating on Aurora Cannabis (TSX:ACB) (NYSE:ACB) and slapped the company with a $0 per share price target. In other words, the analyst said: “Aurora Cannabis’ equity is effectively worthless.”
Report By Grizzly Research Accuses Trulieve of Insider Dealing and Fraud
Image Sourced from Pixabay
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.